- Home
- SVRA vs DVAX Comparison
SVRA vs DVAX Comparison
Compare SVRA & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRA | DVAX |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | SVRA | DVAX |
|---|---|---|
| Price | $5.58 | $15.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | $7.33 | ★ $26.50 |
| AVG Volume (30 Days) | 3.5M | ★ 4.3M |
| Earning Date | 11-12-2025 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $330,514,000.00 |
| Revenue This Year | N/A | $24.63 |
| Revenue Next Year | N/A | $15.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 26.73 |
| 52 Week Low | $1.89 | $9.20 |
| 52 Week High | $7.01 | $15.49 |
Technical Indicators
Market Signals| Indicator | SVRA | DVAX |
|---|---|---|
| Relative Strength Index (RSI) | 41.85 | 89.03 |
| Support Level | $5.47 | $10.78 |
| Resistance Level | $6.64 | $15.43 |
| Average True Range (ATR) | 0.35 | 0.14 |
| MACD | -0.17 | 0.34 |
| Stochastic Oscillator | 7.60 | 98.97 |
Price Performance
Historical ComparisonAbout SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.